The tweet was deleted by the author.
But we saved everything 🙂.
Eyepoint Pharmaceuticals has announced an ambitious pivotal Phase 3 program targeting diabetic macular edema (DME).
The company anticipates dosing its first patient in the first quarter of 2026. This program is reinforced by new preclinical data, which suggests a multi-mechanism of action (MOA) targeted approach, potentially enhancing treatment efficacy. The promising preclinical findings will be presented at the Eyecelerator event during the American Academy of Ophthalmology's 2025 annual meeting. The announcement underscores Eyepoint's commitment to advancing treatment options for DME, a leading cause of vision loss among diabetics.
No output.